AU2003205230A1 - Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes - Google Patents

Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes

Info

Publication number
AU2003205230A1
AU2003205230A1 AU2003205230A AU2003205230A AU2003205230A1 AU 2003205230 A1 AU2003205230 A1 AU 2003205230A1 AU 2003205230 A AU2003205230 A AU 2003205230A AU 2003205230 A AU2003205230 A AU 2003205230A AU 2003205230 A1 AU2003205230 A1 AU 2003205230A1
Authority
AU
Australia
Prior art keywords
diabetes
digenic
diagnosis
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003205230A
Inventor
Ines Barroso
Stephen O. O'Rahilly
Alan J. Schafer
Nicholas J. Waraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of AU2003205230A1 publication Critical patent/AU2003205230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003205230A 2002-01-18 2003-01-17 Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes Abandoned AU2003205230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35040502P 2002-01-18 2002-01-18
US60/350,405 2002-01-18
PCT/US2003/001625 WO2003061583A2 (en) 2002-01-18 2003-01-17 Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes

Publications (1)

Publication Number Publication Date
AU2003205230A1 true AU2003205230A1 (en) 2003-09-02

Family

ID=27613388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003205230A Abandoned AU2003205230A1 (en) 2002-01-18 2003-01-17 Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes

Country Status (2)

Country Link
AU (1) AU2003205230A1 (en)
WO (1) WO2003061583A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208971A1 (en) * 2004-07-28 2009-08-20 Andreas Christ Insulin promoter factor 1 as target/marker of beta cell failure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294559B1 (en) * 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
JP4296608B2 (en) * 1997-08-27 2009-07-15 田辺三菱製薬株式会社 PPAR agonist and antagonist screening method

Also Published As

Publication number Publication date
WO2003061583A9 (en) 2003-11-27
WO2003061583A2 (en) 2003-07-31
WO2003061583A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
IL160917A0 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
IL172507A0 (en) New biological entities and the pharmaceutical or diagnostic use thereof
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
IL180434A0 (en) Human glucagon - like - peptide - 1 modulators and their use in the treatment of diabetes and related conditions
GB2419529B (en) Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
UA83854C2 (en) Use of telmisartan in order to increase insulin sensitivity
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2003202075A1 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
ZA200610786B (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
HUP0201997A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2003102163A8 (en) Methods of diagnosing and treating diabetes and insulin resistance
AU2003219462A1 (en) Defibrillator/monitor with patient specific treatment algorithms
AU2003294856A8 (en) Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
AU2003243427A1 (en) Methods of diagnosing and treating diabetes and insulin resistance
AU2003205230A1 (en) Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003232022A1 (en) USE OF PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) IN THE DIAGNOSIS AND TREATMENT OF CHRONIC LUNG DISEASE AND OTHER PATHOLOGIES
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase